Frailty Heart Failure Study

Frailty in Community Dwelling Older Adults With Heart Failure

A prospective longitudinal cohort study aimed at measuring frailty and its associated risk factors community dwelling older adults aged 65 years or older.

The geriatric domains evaluated will include: frailty status, hearing impairment, visual impairment, polypharmacy, sarcopenia, malnutrition, cognitive impairment, depression, fatigue, sleep difficulties, and disabilities.

The primary outcome is all-cause mortality at 1-year post enrollment.

Study Overview

• Status: Unknown
• Conditions: Heart Failure; Frail Elderly Syndrome

Detailed Description

The overarching research question is as follows: Is frailty predictive of patient-centered outcomes in older adults with heart failure (HF)? Hypotheses regarding this research question are: 1) Frailty is associated with increased 12-month mortality, 2) Frailty is associated with increased 3-month mortality or unplanned hospitalization, 3) Frailty is associated with lower baseline health-related quality of life (HrQOL), and 4) Frailty is associated with worsening HrQOL at 3 months.

There are three specific study objectives. 1) To compare the ability of various frailty measures to predict all-cause mortality, hospitalizations, and HrQOL in patients attending an outpatient HF clinic. 2) To examine the determinants of longitudinal changes in frailty measures over time. Lastly, 3) To examine the clinical and frailty related determinants of fatigue in older adults

A prospective longitudinal cohort study will be conducted at a specialized heart failure (HF) clinic at the Jewish General Hospital (JGH) and Royal Victoria Hospital (RVH). The study aims to measure frailty and its associated risk factors in community dwelling individuals, aged 65 years or older and who have been diagnosed with HF (preserved or reduced ejection fraction) for at least 3 months. The multi-domain geriatric assessment will include questionnaires administered by interview, physical performance tests, body composition analysis using a bioimpedance machine, review of clinically acquired biochemical and imaging tests, and chart review. The geriatric domains evaluated will include: frailty status, hearing impairment, visual impairment, polypharmacy, sarcopenia, malnutrition, cognitive impairment, depression, fatigue, sleep difficulties, and disabilities. Baseline assessment will approximate to 40 minutes of patient contact time while follow up phone interviews at 3 and 12 months will approximate to 20 minutes. Outcome measures such as all-cause mortality, HrQOL, unplanned hospitalization will be assessed at 3 months and 1-year post enrollment.

• Study Type: Observational
• Enrollment (Anticipated): 280

Contacts and Locations

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The study population is determined using the inclusion and exclusion criteria. Study population will be Montreal based.

Description

Inclusion Criteria:

• Community dwelling outpatients
• Aged 65 years or older
• A HF diagnosis with preserved or reduced ejection fraction for at least 3 months
• Agreed to participate and signed an informed consent form

Exclusion Criteria:

• Outpatients with a recent hospital admission within 3 months
• Acutely decompensated HF status at the time of their visit
• Received intravenous (IV) diuretics or IV inotropes within 3 months
• A moribund health status with life expectancy less than 3 months
• Scheduled to undergo a major surgical or percutaneous procedure within 3 months
• Implantation of cardiac resynchronization therapy within the past 3 months or intent to place
• Patients with a history of heart transplant, currently on the transplant list or with an left ventricular device
• Severe neuropsychiatric impairments
• Non -English or French speaking

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
JGH Cohort; This cohort will not be subjected to any intervention.
RVH Cohort; This cohort will not be subjected to any intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All cause mortality at 12 months	All cause mortality (cardiac and non- cardiac causes) assessed using in hospital chart reviews.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
All cause mortality	All cause mortality (cardiac and non- cardiac causes) assessed using in hospital chart reviews.	3 months
Unplanned hospitalization at 3 and 12 months	Unplanned hospitalization (In hospital stay for a minimum of 48 hours) assessed using in hospital chart reviews and self-reported hospitalization.	3 months and 12 months
Health related quality of life at 3 and 12 months measured using the Short Form Health Survey questionnaire (SF-36)	The sub-scales of the SF-36 include, physical functioning, bodily pain, general health, vitality, social and functioning, mental health.	3 months and 12 months

Collaborators and Investigators

• Sponsor: Jewish General Hospital
• Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre
• Investigators: Principal Investigator: Jonathan Afilalo, MD, MSc, Jewish General Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): April 1, 2019
• Primary Completion (Anticipated): November 1, 2020
• Study Completion (Anticipated): November 1, 2020

Study Registration Dates

• First Submitted: March 14, 2019
• First Submitted That Met QC Criteria: March 21, 2019
• First Posted (Actual): March 22, 2019

Study Record Updates

• Last Update Posted (Actual): March 22, 2019
• Last Update Submitted That Met QC Criteria: March 21, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Keywords: frailty, heart failure, mortality, quality of life
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Heart Failure; Frailty
• Other Study ID Numbers: MP-05-2019-1682

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No